Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies

Manya H., Bouchet C., Yanagisawa A., Vuillaumier-Barrot S., Quijano-Roy S., Suzuki Y., ...Daha Fazla

NEUROMUSCULAR DISORDERS, cilt.18, sa.1, ss.45-51, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.nmd.2007.08.002
  • Dergi Adı: NEUROMUSCULAR DISORDERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.45-51
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Defects in O-mannosylation of a-dystroglycan cause some forms of congenital muscular dystrophy (CMD), the so-called alpha-dystroglycanopathies. Six genes are responsible for these diseases with overlapping phenotypes. We investigated the usefulness of a biochemical approach for the diagnosis and investigation of the (alpha-dystroglycanopathies using immortalized lymphoblasts prepared from genetically diagnosed and undiagnosed CMD patients and from control subjects. We measured the activities of protein O-mannose beta 1,2-N-acetylglucosaminyltransferase I (POMGnT1) and protein O-mannosyltransferase (POMT). Lymphoblasts from patients harbouring known mutations in either POMGNT1 or POMT1 showed a marked decrease in POMGnT1 or POMT activity, respectively, compared to controls. Furthermore, we identified pathogenic mutations in POMGNT1, POMT1 or POMT2 in six previously genetically uncharacterised patients who had very low enzyme activity. In conclusion, the lymphoblast-based enzymatic assay is a sensitive and useful method (i) to select patients harbouring POMGNT1, POMT1 or POMT2 mutations; (ii) to assess the pathogenicity of new or already described mutations. (C) 2007 Elsevier B.V. All rights reserved.